Thermo Fisher Scientific (NYSE:TMO) Stock Dropped to “Hold” by DZ Bank

Thermo Fisher Scientific (NYSE:TMO) was downgraded by research analysts at DZ Bank from a “strong-buy” rating to a “hold” rating in a research report issued on Friday, Zacks reports.

Several other equities research analysts have also recently commented on TMO. Piper Sandler started coverage on Thermo Fisher Scientific in a report on Wednesday, September 9th. They issued an “overweight” rating for the company. Barclays boosted their price objective on Thermo Fisher Scientific from $750.00 to $775.00 and gave the stock an “overweight” rating in a research note on Thursday. TD Cowen upped their target price on Thermo Fisher Scientific from $760.00 to $810.00 and gave the company a “buy” rating in a report on Thursday. Morgan Stanley raised their target price on Thermo Fisher Scientific from $650.00 to $730.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Finally, Guggenheim assumed coverage on Thermo Fisher Scientific in a report on Thursday, October 15th. They set a “buy” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $681.00.

Thermo Fisher Scientific Stock Down 0.4%

TMO stock opened at $673.97 on Friday. The company has a current ratio of 1.81, a quick ratio of 1.18 and a debt-to-equity ratio of 0.71. The firm has a 50-day moving average of $645.72 and a two-hundred day moving average of $554.80. Thermo Fisher Scientific has a 12 month low of $435.27 and a 12 month high of $705.78. The company has a market cap of $249.20 billion, a price-to-earnings ratio of 35.55, a PEG ratio of 2.81 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, topping the consensus estimate of $6.40 by $0.28. The business had revenue of $12.14 billion for the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.79 EPS. As a group, analysts forecast that Thermo Fisher Scientific will post 25.20 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Michael D. Shafer sold 25,500 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the transaction, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. This represents a 54.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the sale, the vice president directly owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 73,768 shares of company stock worth $44,122,820 in the last 90 days. 0.33% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

Hedge funds have recently modified their holdings of the business. Polaris Financial Partners purchased a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $32,000. Kilter Group LLC purchased a new stake in Thermo Fisher Scientific during the second quarter worth approximately $25,000. Legacy Wealth Managment LLC ID lifted its stake in Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after purchasing an additional 22 shares during the last quarter. Allied Private Wealth LLC acquired a new position in Thermo Fisher Scientific in the second quarter valued at approximately $26,000. Finally, Pingora Partners LLC acquired a new position in Thermo Fisher Scientific in the second quarter valued at approximately $30,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations. Thermo Fisher reported adjusted earnings of $6.68 per share versus the $6.40 consensus, while revenue rose 9.1% year over year to $12.14 billion, topping estimates of $11.95 billion. TMO Q3 deep dive: pharma demand, AI integration, and end-market recovery drive momentum
• Positive Sentiment: Analysts raised their valuation targets. TD Cowen increased its target to $810 and maintained a buy rating, while Stifel raised its target to $775 and Baird lifted its target to $756 with an outperform rating. These revisions imply meaningful upside from recent trading levels. TD Cowen analyst ratings
• Positive Sentiment: Improving end markets support the growth outlook. Investor commentary highlighted a broad-based recovery across life-science markets, including pharmaceutical demand, AI-related applications and other research tools. Erste Group also modestly raised its FY2027 EPS estimate to $27.58 from $27.51. Thermo Fisher benefits on broad-based recovery
• Neutral Sentiment: Secular market growth provides a longer-term tailwind. Industry forecasts call for strong expansion in next-generation sequencing kits and peptide synthesis, markets in which Thermo Fisher participates, although these reports do not directly change near-term earnings. NGS kits market forecast
• Negative Sentiment: Options activity signals caution. Heavy put-option buying indicates that some traders are hedging against, or positioning for, a pullback. The muted reaction to the earnings beat may also reflect elevated expectations and a relatively rich valuation. Thermo Fisher stock sees heavy put option buying

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.